Accelerate Diagnostics, Inc. AXDX NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score

18/100

0/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Accelerate Diagnostics, Inc. (AXDX) generated $-24.19M in operating cash flow for fiscal year 2024. After capital expenditures of $0.00, free cash flow was $-24.7M.

Free cash flow margin was -211.2% of revenue. Cash conversion ratio was 0.48x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
MOAT (29/100, Fail) — limited free cash flow weakens the competitive position
INCOME (10/100) — Cash conversion ratio was 0.48x suggests some earnings are non-cash items

Overall SharesGrow Score: 17/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

18/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

29/100

Proven by this page

GROWTH

48/100

→ Income

✗

INCOME

10/100

→ Income

Accelerate Diagnostics, Inc. Cash Flow History

Metric	TTM	FY2024	FY2023	FY2022	FY2021
Operating Cash Flow	$-24.19M	$-24.19M	$-40.2M	$-48.73M	$-47.32M
Capital Expenditure	$-509K	$0.00	$-1.04M	$-554K	$-603K
Free Cash Flow	$-24.7M	$-24.7M	$-41.23M	$-49.28M	$-47.93M